Toxoplasma Seroconversion with Negative or Transient
Immunoglobulin M in Pregnant Women: Myth or Reality? A French Multicenter Retrospective Study P rimary toxoplasmic infection during pregnancy can induce transplacental transmission of Toxoplasma gondii, resulting in a congenital infection (1, 2, 3) with possible severe outcomes for the fetus, including chorioretinitis, intracranial calcifications, hydrocephalus, and even stillbirth, especially if the congenital infection is acquired early in the pregnancy (4, 5, 6) . The majority of infants infected later in pregnancy are asymptomatic at birth, with sequelae potentially occurring later in life (7, 8, 9, 10) . Since pregnant women are generally asymptomatic during the course of Toxoplasma infection, the diagnosis is based on serological methods (11) . Thus, seronegative women can be monitored during pregnancy and prophylactic recommendations provided (2) . Consequently, serological tests for IgM and IgG antibodies against T. gondii are commonly used as initial screening approaches in the laboratory diagnosis of toxoplasmosis. IgM anti-T. gondii antibodies are known to be a marker of acute infection and appear earlier and decline faster than IgG antibodies. IgM is frequently the first antibody isotype to be detected after the primary infection. The diagnosis of recently acquired toxoplasmosis is usually based on the detection of specific IgM antibodies, followed by the detection of specific IgG antibodies 1 to 3 weeks later with confirmatory tests as described by the French National Reference Center for Toxoplasmosis (12) . Toxoplasma seroconversion is thus defined by specific IgG antibodies appearing after IgM antibodies (2) . However, the serological diagnosis of toxoplasmosis is very complex and has been discussed extensively in the published literature (13, 14, 15) . The interpretation of serological tests is complicated by the long-term persistence of specific IgM and the detection of either IgM alone or IgG alone in a previously seronegative pregnant woman (2) . Consequently, serological tests other than those for IgG and IgM detection have been developed to facilitate the diagnosis of seroconversion. The measurement of IgG avidity was developed almost 20 years ago to exclude any infection acquired in the preceding 3 or 4 months using most commercial tests (16, 17, 18, 19, 20, 21, 22, 23, 24) . Immunoblot analysis (Toxo II IgG test; LDBio, Lyon, France) may promptly confirm the seroconversion when IgG concentrations detected with routine tests are negative or equivocal (25, 26, 27) . In fact, the appearance of IgM alone might be difficult to interpret because it can be due to nascent toxoplasmosis seroconversion or a nonspecific IgM reaction (28) .
Detection of anti-Toxoplasma IgG antibodies alone in previously seronegative pregnant women is so rarely observed that the serological interpretation is difficult. With the exception of cases of immunoglobulin injections and blood transfusions reported in the literature (29) , no data have been published showing the presence of anti-Toxoplasma IgG antibodies with negative or borderline IgM titers in a pregnant woman known to be negative for Toxoplasma antibodies shortly before that test. Laboratories of the French National Reference Center for Toxoplasmosis have been confronted with this situation in their routine work. To investigate these complex situations, we surveyed these laboratories. Twelve of them submitted 26 cases of atypical results obtained in the serodiagnosis of toxoplasmosis over a 10-year period (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . Thus, the aim of our work was to analyze the serological results as they have been presented in real practice, the treatments prescribed to the pregnant women, and the results of prenatal and postnatal follow-up of these cases of atypical seroconversion with negative or borderline IgM titers.
MATERIALS AND METHODS

Patients.
We analyzed the results of serological testing in the 48 laboratories of the French National Reference Center for Toxoplasmosis in order to evaluate their difficulties in interpreting atypical seroconversions in their daily practice of toxoplasmosis diagnosis. Ten towns (twelve medical centers) responded to our request, and we collected 26 cases of seroconversion with negative or low-positive IgM titers among approximately 4,500 seroconversions detected between 2001 and 2011 (0.58%). The number of exceptional serological patterns (IgG seroconversion in the absence of an IgM response) was low at 26 of approximately 800,000 patients tested (1, 200 ,000 serologies). The serological results of 120 serum samples collected from the 26 patients were analyzed. These 26 cases had been selected because the IgG tests were negative with at least one sample and then positive with two to six samples, thus demonstrating a real seroconversion. The IgM tests were negative or borderline by screening or confirmatory techniques. [29] or by bioMérieux), the Toxo-Screen test (bioMérieux), the Toxo II IgG Western blot test (LDBio, Lyon, France), the high-sensitivity direct agglutination (HSDA) test (house-made) (30, 31) , and the Toxo indirect hemagglutination test (Fumouze Diagnostics, le Malesherbes, Levallois Perret, France). The dye test, first described by Sabin and Feldman 60 years ago, is still the reference method for specific antibody (IgG) detection. However, this assay, based on live T. gondii, is now used in only a few laboratories (two laboratories in our study). Confirmatory tests for IgM detection were the immunosorbent agglutination assay (ISAGA-M from bioMérieux or ICT-M, an in-house immunocapture test for IgM [31] ) and the immunofluorescence antibody test (IFAT, produced by bioMérieux or in-house).
The IgA antibodies were detected by the ISAGA-A (bioMérieux), the ICT-A (in-house) (31) , or the Platelia Toxo IgA (Bio-Rad). In addition, the level of IgG avidity was determined using the Vidas Toxo IgG avidity assay (bioMérieux) in 4/10 laboratories, the Platelia Toxo IgG avidity assay (Bio-Rad) in 2/10 laboratories, and the Architect Toxo IgG avidity assay (Abbott Diagnostic) in 1/10 laboratories. All commercially available assays were performed according to the manufacturers' recommendations, and the results are expressed in IU/ml or as indices. The cutoff or equivocal zone values of IgG, IgM, IgA, and IgG avidity are summarized in Table 1 .
Maternal treatment and prenatal diagnosis. When maternal infection acquired during pregnancy was highly suspected, the mother was treated with spiramycin at the standard dosage of 9 ϫ 10 6 units per day until delivery (2). In some cases, amniocentesis was performed after 16 weeks of gestation and at least 4 weeks after maternal infection (32) . Prenatal diagnosis was based on the detection of T. gondii DNA by PCR (33, 34) and, in most reference centers, on the detection of the parasite after mouse inoculation. Moreover, ultrasound surveillance was scheduled every month to carefully monitor fetal development as recommended by the French National Reference Center for Toxoplasmosis (see http://www.perinat-france.org/guide/cnr-centre -national-de-reference-de-la-toxoplasmose-16-386.php).
Follow-up of newborns. At birth, each neonate underwent thorough clinical and neurological check-ups (transfontanellar ultrasound examination) and an examination of the ocular fundus. Parasitological and immunological tests were used during the first year of life to diagnose potential congenital toxoplasmosis (see reference 8 and http: //www.perinat-france.org/guide/cnr-centre-national-de-reference-de -la-toxoplasmose-16-386.php). Standard methods for the detection of specific Toxoplasma antibodies (IgG, IgM, and IgA), such as the enzyme immunoassay (EIA) and immunosorbent agglutination assay (ISAGA or ICT), were combined with Western blotting or an enzymelinked immunofiltration assay (ELIFA) (31) to distinguish maternal antibodies, transmitted either passively (IgG) or by leakage (IgM), and neonatal neosynthesized antibodies. The parasitological examination of placental tissue was sometimes used to diagnose a congenital Toxoplasma infection at birth. However, serological follow-up of the in- a In the equivocal zone, the lower value is the limit of negativity, and the higher value is the limit of positivity. 
RESULTS
Anti-Toxoplasma IgG results. Results of the anti-Toxoplasma
IgG tests concerning the 26 cases in this study are detailed in Tables 2, 3, and 4. In all cases for all techniques, the results of the first serum samples were negative. Then, IgG antibodies appeared in the second or third serum sample. In three cases ( IgG avidity results. The IgG avidity assay was performed on 26 samples collected from 17 patients. Two serum samples from one patient (case 6) revealed high avidity, while 24 samples from 16 patients exhibited low avidity. High avidity excluded a Toxoplasma infection acquired less than 4 months earlier.
Maternal treatment and prenatal diagnosis. Of the 26 patients, 22 (84.6%) were treated with spiramycin from the time that the IgG appeared until delivery, and one received no treatment (Table 5 ). We had no information about the treatment for three patients. PCR analysis of the amniotic fluid was performed on samples from 11 patients, and the results were always negative. Amniotic fluid was not collected in 13 cases, and no information was available in two cases.
Follow-up of newborns. The postnatal serological follow-up period was long enough to definitively exclude congenital toxoplasmosis in 12 cases (Table 5 ). In 10 cases, biological, clinical, radiological, and ophthalmological examinations of the newborns at birth did not reveal any abnormalities, but no information was available concerning their follow-up. In four cases, we had no information about the newborns.
DISCUSSION
Serological diagnosis is the main approach for defining the risk of primary Toxoplasma infection in a pregnant woman. The measurement of IgG, IgM, IgA, and IgG avidity by different methods usually allows doctors to establish the immunologic status of a patient and to diagnose seroconversion (2) . The difficulties encountered in the serodiagnosis of toxoplasmosis in pregnant women have been underlined for a long time (15, 29, 35, 36) . The absence of IgG antibodies before, or early in, pregnancy enables the identification of women at risk for acquiring infection (12) . Thus, in the daily routine, serological results showing positive IgG and negative or transient IgM in previously negative pregnant women can create interpretation difficulties.
Different factors might explain such results: (i) the injection of gamma globulins or a blood transfusion, which might have led to the appearance of exogenous anti-Toxoplasma IgG (29); (ii) immune disorders or other pathologies in the patient, which might have led to the presence of unusual antibody subsets; (iii) toxoplasmosis serological reactivation or reinfection in chronically infected patients with previously very low IgG residual titers below the detection threshold; and (iv) toxoplasmosis that was recently acquired but with a very unusual serological profile. The first two factors should be investigated before the others, and if appropriate, the pregnant women should be considered seronegative and be given hygiene recommendations to avoid toxoplasmic infection. The first factor (injection of gamma globulins) was ruled out for the 26 cases described in our study. Concerning immune disorders or other pathologies, only varicella symptoms were observed in 1/26 cases (Table 2, case 18). To our knowledge, while viral infections are known to generate positive anti-Toxoplasma IgM, no data can be found in the literature about the influence of viral infection on the detection of anti-Toxoplasma IgG. The third factor is toxoplasmic serological reactivation or reinfection. In chronic toxoplasmosis, IgG could exceptionally decrease to below the cutoff level of the IgG assay, and in such cases, the reappearance of IgG is not a real seroconversion but a serological reactivation. An additional exposure to T. gondii could trigger an immediate IgG response without an (or with a weak) IgM response (37) .
In the case of high IgG avidity results and the absence of gamma globulin injection or transfusion, IgG detection is the paramount criterion of chronic toxoplasmosis (12) . In one case of our study (Table 2 , case 6), the result of the avidity assay was high, but it is necessary to stress that high avidity has been observed, if rarely, in serum sampled 1 month after infection (21) . However, the determination of IgG avidity in an atypical serological profile is necessary (12) .
The fourth factor (recently acquired toxoplasmosis with an atypical serological profile) is often considered by medical biologists and clinicians. In fact, in our study, 22/26 patients were treated with spiramycin as a consequence of such serological results, and an amniocentesis was performed for 11/26 patients. However, the results of the infants' follow-ups did not reveal any case of congenital toxoplasmosis. In fact, our results definitively excluded toxoplasmosis in 12 cases and revealed no neonatal abnormality or any serological argument for congenital toxoplasmosis at birth in 10 cases. The results of IgG confirmatory techniques were always the same as those of the IgG screening techniques, i.e., negative on the first serum sample and positive on the other successive serum samples. Moreover, the avidity findings were low in 16/17 cases. Typically, in seroconversion, the appearance of IgG is linked to high IgM and rising IgM levels (15) . In our study, IgM antibodies were not detected in 15 cases, although we cannot totally exclude that they could have been transient and present during only a very short time period so that they were not observed in the samples at the time they were collected. If the interval between two samplings had been shorter, IgM might have been observed. In the 11 other cases, IgM antibodies were detected at low levels by the Liaison and Platelia tests (2 cases) or with a positive index by only the ISAGA test (9 cases). The detection of IgM usually indicated toxoplasmosis. However, considering that these IgM antibodies were TABLE 5 Gestational age at time of IgG conversion, maternal treatment, prenatal diagnosis, and infant follow-up of the 26 women with atypical seroconversion detected at low levels for a very short time period and that they tested positive with only one or two techniques (only the ISAGA test or only the Platelia and Liaison tests) and quickly disappeared, anti-Toxoplasma IgM antibodies were probably not specific. The persistence of IgG in all successive serum samples might have suggested a life-long immunity to toxoplasmosis, but the follow-up time of these women was not long enough (from 2 weeks to 6 months, depending on the patient).
A pregnant woman who tests negative requires regular checkups for seroconversion (2) . In fact, the frequency of check-ups varies from one country to another, depending on the screening programs adopted in each country. Seroconversion without IgM can be observed in France thanks to monthly routine testing of seronegative pregnant women. Such results in a previously seronegative pregnant woman should motivate further exploratory tests, as defined by the French National Reference Center for Toxoplasmosis (12) . Double-checking IgG results using other techniques is necessary to confirm the first results, and the avidity test is necessary. It is also important to collect all information about the clinical history of a pregnant woman (immune disorders, other pathology, transfusion, and previous results of toxoplasmosis serology). The interpretation of seroconversion with either no IgM or transient IgM levels may then be discussed.
It is noteworthy that the pathophysiology of toxoplasmosis is far from being fully understood, and the pathogenesis mechanism is complex because the parasite and host specificities are interrelated (38) . In such complex serological cases as those that we analyzed, we think that it is cautious to initiate treatment and to follow up with pregnant women (4) . Puncture and analysis of the amniotic fluid may also be discussed, depending on the gestational age at which the IgG antibodies appeared.
